Step 2: Observe the mandatory washout period
Research shows GLP-1 receptor agonists effectively reduce visceral fat, though whether this reduction is preferential compared to subcutaneous fat continues to be investigated
Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Frequently Asked Questions Will I feel appetite suppression on my first injection of tirzepatide
Low adoption of weight loss medications: A comparison of prescribing patterns of anti-obesity pharmacotherapies and SGLT2s
For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk